Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1079-1084

  Rivera, Rosario S ^a,b   Gunduz, Mehmet ^a,c   Nagatsuka, Hitoshi ^a   Gunduz, Esra ^a   Cengiz, Beyhan ^a   Fukushima, Kunihiro ^a   Beder, Levent Bekir ^c   Pehlivan, Davut ^d   Yamanaka, Noboru ^c   Shimizu, Kenji ^a   Nagai, Noriyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE EAST   (Philippines)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

EphA2; Head and neck squamous cell carcinoma; Immunohistochemistry; Loss of heterozygosity; mRNA expression

Indexed keywords

EPHRIN RECEPTOR A2; MESSENGER RNA; LIGAND;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; BIOLOGICAL MODEL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; METASTASIS; MIDDLE AGED;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LIGANDS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASM METASTASIS; RECEPTOR, EPHA2; RNA, MESSENGER;

EID: 47549099026     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1079     Document Type: Article

References (31)

1. Cheng N, Brantley DM and Chen J: The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13: 75-85, 2002.
2. Durbin L, Brennan C, Shiomi K, et al: Eph signaling is required for segmentation and differentiation of the somites. Genes Dev 12: 3096-3109, 1998.
3. Friedman GC and O'Leary DD: Eph receptor tyrosine kinases and their ligands in neural development. Curr Opin Neurobiol 6: 127-133, 1996.
4. Lindberg RA and Hunter T: cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 10: 6316-6324, 1990.
5. Tuzi NL and Gullick WJ: eph, the largest known family of putative growth factor receptors. Br J Cancer 69: 417-421, 1994.
6. Rosenberg IM, Goke M, Kanai M, Reinecker HC and Podolsky DK: Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 273: G824-G832, 1997.
7. Pandey A, Shao H, Marks RM, Polverini PJ and Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268: 567-569, 1995.
8. Piaskowski S, Rieske P, Szybka M, et al: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol 71: 27-30, 2005.
9. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM and Ikegaki N: ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40: 371-374, 1997.
10. Griffin CA, Hruban RH, Long PP, Miller N, Volz P, Carson B and Brem H: Chromosome abnormalities in meningeal neoplasms: do they correlate with histology? Cancer Genet Cytogenet 78: 46-52, 1994.
11. White PS, Thompson PM, Gotoh T, et al: Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24: 2684-2694, 2005.
12. Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12: 353-360, 2006.
13. Herrem CJ, Tatsumi T, Olson KS, et al: Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 11: 226-231, 2005.
14. Kinch MS, Moore MB and Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613-618, 2003.
15. Miyazaki T, Kato H, Fukuchi M, Nakajima M and Kuwano H: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103: 657-663, 2003.
16. Saito T, Masuda N, Miyazaki T, et al: Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11: 605-611, 2004.
17. Thaker PH, Deavers M, Celestino J, et al: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 5145-5150, 2004.
18. Xu F, Zhong W, Li J, Shanshen Z, Cui J, Nesland JM and Suo Z: Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res 25: 2943-2950, 2005.
19. Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R and Nesland JM: Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol 94: 312-319, 2004.
20. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001.
21. Gunduz M, Ouchida M, Fukushima K, et al: Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res 60: 3143-3146, 2000.
22. Gunduz M, Ouchida M, Fukushima K, et al: Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21: 4462-4470, 2002.
23. Temnykh S, DeClerck G, Lukashova A, Lipovich L, Cartinhour S and McCouch S: Computational and experimental analysis of microsatellites in rice (Oryza sativa L.): frequency, length variation, transposon associations, and genetic marker potential. Genome Res 11: 1441-1452, 2001.
24. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
25. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
26. Walker-Daniels J, Riese DJ II and Kinch MS: c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 1: 79-87, 2002.
27. Herath NI, Spanevello MD, Sabesan S, et al: Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 6: 144, 2006.
28. Dohn M, Jiang J and Chen X: Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20: 6503-6515, 2001.
29. Zantek ND, Walker-Daniels J, Stewart J, et al: MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 7: 3640-3648, 2001.
30. Kikawa KD, Vidale DR, Van Etten RL and Kinch MS: Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277: 39274-39279, 2002.
31. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G and Chiarugi P: EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280: 34008-34018, 2005.